Reuters: Atos Makes $10 Bln Takeover Bid For DXC Technology

Moderna To Supply 40 Mln Doses Of COVID-19 Vaccine To South Korea

Moderna Inc. (MRNA) confirmed Thursday that it has reached a supply agreement with the government of the Republic of Korea to provide 40 million doses of its COVID-19 Vaccine.

As per the terms of the proposed agreement, deliveries would begin in May 2021.

The COVID-19 Vaccine is not currently approved for use in South Korea. But the company will work with regulators to pursue the necessary approvals prior to distribution, Moderna said in a statement.

Moderna said Tuesday that it was engaged in discussions with the government of South Korea to potentially provide 40 million or more doses of the COVID-19 Vaccine.

Earlier today, FedEx Express Canada and Innomar Strategies said that they have begun to distribute Moderna COVID-19 vaccine across Canada.

The Canadian roll-out comes shortly after the FedEx network started delivering both the Pfizer-BioNTech and later the Moderna vaccines across the U.S., beginning mid-December.

British drug major AstraZeneca Plc.’s COVID-19 vaccine, co-developed by the University of Oxford, was approved on Wednesday for emergency supply in the UK.

The Pfizer-BioNTech COVID-19 vaccine was approved in the U.S., which started mass vaccination on December 14. Moderna’s COVID-19 vaccine mRNA-1273 also was approved for emergency use in the U.S. on December 18.

Congress Certifies Joe Biden’s Election Victory

A joint session of Congress has certified the election victory of Joe Biden and Kamala Harris, clearing the final hurdle for the Democrat leaders to become the next president and vice-president of the United States, respectively.

The confirmation after counting the Electoral College votes was only a formality, but unexpected developments delayed the process Wednesday.

As members of both the Senate and the House of Representatives convened, dozens of Trump-supporters stormed the Capitol and disrupted the proceedings.

Four people, including one woman shot by police, died in the rampage.

The Congress reconvened at around 8 pm after the building was cleared. Republicans introduced motions raising objections to the electoral votes in Pennsylvania and Arizona, but both the chambers voted them out without debate.

The session certified the original vote tally – Biden’s 306 votes to Trump’s 232.

RNC Official Hit With The Cold, Hard Truth After Decrying ‘Domestic Terrorism’

The communications director of the Republican National Committee faced swift backlash after he condemned Wednesday’s pro-Trump U.S. Capitol riot as “domestic terrorism.”

People on Twitter were having none of Michael Ahrens’ post, suggesting it was far too little and far too late from an official at the political outfit that has thrown its wholehearted support behind President Donald Trump over the last four years and has questioned President-elect Joe Biden’s election victory. Trump lost the election ― despite his lies to the contrary.

Critics swiftly reminded Ahrens of the dangerous role the RNC, the president, many Republicans and pro-Trump media played in stoking the violence that unfurled on the day that Congress certified Biden’s win. 

Tweets railing against Wednesday’s violence were also posted on the RNC’s official feed and by RNC Chair Ronna McDaniel.

All were met with similar disdain.

RELATED…


PerkinElmer To Acquire Oxford Immunotec – Quick Facts

PerkinElmer, Inc. (PKI) and Oxford Immunotec Global PLC (OXFD) have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec. Oxford shareholders will be entitled to receive $22.00 in cash for each outstanding ordinary share. This value the company’s entire issued and to be issued ordinary share capital at approximately $591 million.

Headquartered in Abingdon, UK, Oxford Immunotec is recognized as a global leader of proprietary test kits for latent tuberculosis.

PerkinElmer anticipates the deal to be modestly accretive to non-GAAP earnings in year-one following the close.

Lindsay Corporation Announces Retreat In Q1 Profit

Lindsay Corporation (LNN) announced a profit for first quarter that fell from last year.

The company’s earnings totaled $7.10 million, or $0.65 per share. This compares with $8.35 million, or $0.77 per share, in last year’s first quarter.

Analysts had expected the company to earn $0.75 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter fell 0.8% to $108.49 million from $109.39 million last year.

Lindsay Corporation earnings at a glance:

-Earnings (Q1): $7.10 Mln. vs. $8.35 Mln. last year.
-EPS (Q1): $0.65 vs. $0.77 last year.
-Analysts Estimate: $0.75
-Revenue (Q1): $108.49 Mln vs. $109.39 Mln last year.

Reuters: Atos Makes $10 Bln Takeover Bid For DXC Technology

French IT consulting group Atos SE has made a takeover bid to acquire U.S.-based DXC Technology Co. (DXC) for more than $10 billion, Reuters reported Thursday, citing two sources with knowledge of the matter. Shares of DXC Technology are rising more than 10 percent in pre-market activity.

According to the report, Atos is working with advisors on a possible deal for DXC Technology and made a formal approach earlier this week. However, talks are still at a preliminary stage.

An acquisition of DXC Technology would bolster Atos’ presence in the U.S. and provide it with access to a wide range of clients and B2B products, the report added.

In November 2020, DXC Technology announced the sale of its U.S. State and Local Health and Human Services (State & Local HHS) business to Veritas Capital for $5.0 billion in cash.